- for
evaluating biosimilars. The EMA has
granted marketing authorizations for more than 50
biosimilars since 2006. The
first biosimilar of a monoclonal...
- Union. In 2018, the
biosimilars Halimatoz, Hefiya, Hyrimoz, and
Hulio were
approved for use in the
European Union.
Adalimumab biosimilars became available...
-
Rituximab Patent".
Center for
Biosimilars.
Retrieved 27 July 2024. "
Biosimilars of Rituximab".
Generics and
Biosimilars Initiative. 14
April 2017. Archived...
-
marketed as
Lyumjev by Lilly, is
similar to the
names of
biosimilars, it is not a
biosimilar insulin.
Insulin lispro-aabc is
simply a
faster formulation...
- follow-on
biosimilars will
exhibit variability in
specific variants over time. The
safety and
clinical performance of both
originator and
biosimilar biopharmaceuticals...
-
Group AG is a
Swiss company that
focuses on
generic pharmaceuticals and
biosimilars.
Prior to
October 2023, it was part of a
division of
Novartis that was...
-
States in 1998, and in the
European Union in
August 1999.
Infliximab biosimilars have been
approved in the EU (2013), in ****an (2014), and in the United...
- quality-****ured
biosimilars Afatinib and
gefitinib are
alternatives Pembrolizumab is an alternative,
including quality-****ured
biosimilars Enzalutamide is...
-
monoclonal antibodies,
differ biologically from small-molecule drugs.
Biosimilars have
active pharmaceutical ingredients that are
almost identical to the...
-
Center for
Biosimilars®". "
Biosimilars and
Interchangeable Biologics:
Tactical Elements". "Fundamentals of
Modern Bioprocessing". "
Biosimilarity: The FDA...
